The role of ceramide trihexoside (globotriaosylceramide) in the diagnosis and follow-up of the efficacy of treatment of Fabry disease: a review of the literature.

No abstract is available for this paper.

• Publication year

  2006

• Venue

  Cardiovascular & Hematological Agents in Medicinal Chemistry

• Publication date

  2006-09-30

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.2174/187152506778520718PMID 17073606
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• A multi-omics-empowered framework for precision diagnosis and treatment of lysosomal diseases

  2025cites this paper
• Lectin-Based Substrate Detection in Fabry Disease Using the Gb3-Binding Lectins StxB and LecA

  2025cites this paper
• Fabry disease and kidney involvement: starting from childhood to understand the future

  2021cites this paper
• Structural Diversities of Lectins Binding to the Glycosphingolipid Gb3

  2021cites this paper
• New opportunities and challenges of venom-based and bacteria-derived molecules for anticancer targeted therapy.

  2020cites this paper
• Environmental Cues Modulate Microglial Cell Behavior Upon Shiga Toxin 2 From Enterohemorrhagic Escherichia coli Exposure

  2020cites this paper
• Biomarkers of Fabry Nephropathy: Review and Future Perspective

  2020cites this paper
• Antitumor Potential of Marine and Freshwater Lectins

  2019cites this paper
• Safety and effectiveness of enzyme replacement therapy with agalsidase alfa in patients with Fabry disease: Post-marketing surveillance in Japan.

  2019cites this paper
• Sphingolipidoses and Related Disorders

  2018cites this paper
• Adaptive pathway development for Fabry disease: a clinical approach.

  2018cites this paper
• New markers of Fabry disease

  2017cites this paper
• UvA-DARE ( Digital Academic Repository ) Glycosphingolipids and the central regulation of metabolism Sugar analogues as research tools

  2017cites this paper
• Sequential One-Pot Multienzyme Chemoenzymatic Synthesis of Glycosphingolipid Glycans.

  2016cites this paper
• Tandem Mass Spectrometry of Sphingolipids: Applications for Diagnosis of Sphingolipidoses.

  2016cites this paper
• Biomolecules damage and redox status abnormalities in Fabry patients before and during enzyme replacement therapy.

  2016cites this paper
• Pharmacological Chaperones as Potential Therapeutics for Lysosomal Storage Disorders: Preclinical Research to Clinical Studies

  2016cites this paper
• Variations in the GLA gene correlate with globotriaosylceramide and globotriaosylsphingosine analog levels in urine and plasma.

  2015cites this paper
• Fabry’s disease: an example of cardiorenal syndrome type 5

  2015cites this paper
• Human breast cancer and lymph node metastases express Gb3 and can be targeted by STxB-vectorized chemotherapeutic compounds

  2014cites this paper
• Gaucher disease and Fabry disease: new markers and insights in pathophysiology for two distinct glycosphingolipidoses.

  2014cites this paper
• Reduced glucosylceramide in the mouse model of Fabry disease: correction by successful enzyme replacement therapy.

  2014cites this paper
• Chemical Biology of Membranes and Therapeutic Delivery Director :

  2014cites this paper
• Building a glucosylation platform in E. coli through Metabolic Engineering

  2013cites this paper
• Quantification of globotriaosylsphingosine in plasma and urine of fabry patients by stable isotope ultraperformance liquid chromatography-tandem mass spectrometry.

  2013cites this paper
• Migalastat HCl Reduces Globotriaosylsphingosine (Lyso-Gb3) in Fabry Transgenic Mice and in the Plasma of Fabry Patients

  2013cites this paper
• An AQP1 allele associated with Co(a–b–) phenotype

  2013cites this paper
• Fabry meets Markov: evaluating biochemistry, disease course and costs in support of health care policy

  2013cites this paper
• Sphingolipid Disorders and the Neuronal Ceroid Lipofuscinoses or Batten Disease (Wolman Disease, Cholesteryl Ester Storage Disease, and Cerebrotendinous Xanthomatosis)

  2013cites this paper
• Fabry disease, enzyme replacement therapy and the significance of antibody responses

  2012cites this paper
• Long-Term Effect of Antibodies against Infused Alpha-Galactosidase A in Fabry Disease on Plasma and Urinary (lyso)Gb3 Reduction and Treatment Outcome

  2012cites this paper
• Urinary total globotriaosylceramide and isoforms to identify women with Fabry disease: a diagnostic test study.

  2011cites this paper
• Maladie de Fabry : une maladie du métabolisme par déficit d’une enzyme lysosomale (alpha-galactosidase), de transmission héréditaire liée au chromosome X accessible au traitement enzymatique de substitution

  2011cites this paper
• Biomarkers in the diagnosis of lysosomal storage disorders: proteins, lipids, and inhibodies

  2011cites this paper
• Sphingolipid and Glycosphingolipid Metabolic Pathways in the Era of Sphingolipidomics

  2011cites this paper
• Reduction of elevated plasma globotriaosylsphingosine in patients with classic Fabry disease following enzyme replacement therapy.

  2011cites this paper
• Biomarkers for Fabry Disease

  2010cites this paper
• Fabry disease

  2010cites this paper
• Therapeutic goals in the treatment of Fabry disease

  2010cites this paper
• Management of Fabry Disease with Agalsidase Treatment

  2010cites this paper
• Autophagosome maturation is impaired in Fabry disease

  2010cites this paper
• Effects of enzyme replacement therapy in Fabry disease—A comprehensive review of the medical literature

  2010cites this paper
• Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease.

  2010influential citation
• Laboratory Diagnosis of Fabry Disease

  2010cites this paper
• Agalsidase alfa for enzyme-replacement therapy in Fabry disease

  2010cites this paper
• Fabry disease: a review of current management strategies.

  2010cites this paper
• Evidence for a role of sphingosine-1 phosphate in cardiovascular remodelling in Fabry disease.

  2010cites this paper
• Enzyme therapy in Fabry disease: severe adverse events associated with anti-agalsidase cross-reactive IgG antibodies.

  2009cites this paper
• Efficacité clinique de l’enzymothérapie dans la maladie de Fabry. Analyse critique

  2009cites this paper
• [Clinical efficacy of enzyme replacement therapy in Fabry disease. A critical review].

  2009cites this paper
• Actualités sur la maladie de Fabry : un diagnostic plus précoce pour un traitement plus efficace

  2009cites this paper
• Biomarkers for lysosomal storage disorders: identification and application as exemplified by chitotriosidase in Gaucher disease

  2008cites this paper
• Elevated globotriaosylsphingosine is a hallmark of Fabry disease

  2008cites this paper
• Enzyme replacement therapy with agalsidase alfa in a cohort of Italian patients with Anderson–Fabry disease: testing the effects with the Mainz Severity Score Index

  2008cites this paper
• Ibland tänkte han sorgset: "Varför?" och ibland tänkte han: "Därför!" och ibland tänkte han: "Således!"

  2007cites this paper
• [What is new in Fabry disease?].

  2007cites this paper
• Safety and pharmacokinetics of agalsidase alfa in patients with Fabry disease and end-stage renal disease.

  2007cites this paper
• Clinical results of enzyme replacement therapy in Fabry disease: a comprehensive review of literature

  2007cites this paper
• Studies on the genetic basis of Pk, P and P1 blood group antigen expression

  2007cites this paper
• Actualités sur la maladie de Fabry

  2007cites this paper
• The pharmacology of multiple regimens of agalsidase alfa enzyme replacement therapy for Fabry disease

  2007influential citation
• Weekly enzyme replacement therapy may slow decline of renal function in patients with Fabry disease who are on long-term biweekly dosing.

  2007cites this paper
• Lysosomes

  1966cites this paper
• Enzyme replacement therapy with agalsidase alfa in a cohort of Italian patients with Anderson-Fabry disease: testing the effects with FLORE Repository istituzionale dell'Università degli Studi di Firenze

  year unknowncites this paper